Most health insurance plans cover immunotherapy when it’s used for an FDA-approved indication and deemed medically necessary, but approval often requires prior authorization and can involve significant out-of-pocket costs. The specifics depend on your insurance type, the cancer being treated, and whether the drug is being used for its approved purpose.
How Medicare Covers Immunotherapy
Medicare Part B covers many cancer treatment drugs administered through an IV in an outpatient clinic or doctor’s office, which includes most immunotherapy infusions. Some oral cancer treatments are also covered. After you meet your deductible, you’re typically responsible for 20% coinsurance, meaning Medicare pays 80% of the approved amount. For drugs that can cost tens of thousands of dollars per infusion cycle, that 20% adds up quickly.
If your doctor accepts Medicare assignment, they agree to charge only what Medicare approves, so you won’t face surprise balance billing. Medicare Advantage plans (Part C) must cover everything Original Medicare covers, but they may use different networks and cost-sharing structures. One study of off-label immunotherapy use found that Original Medicare patients paid an average of $7,436 out of pocket, while Medicare Advantage patients averaged $1,248 for similar treatments.
Private Insurance and Prior Authorization
Private insurers like UnitedHealthcare use National Comprehensive Cancer Network (NCCN) guidelines to decide whether an immunotherapy drug is medically necessary. If your oncologist requests a treatment that follows NCCN-recommended regimens, it’s generally approved. The insurer checks the cancer type, stage, and whether the specific drug is recommended for your situation. Treatments rated with strong evidence (categories 1, 2A, and 2B) are considered proven. Those with the weakest evidence (category 3) are classified as unproven and less likely to be covered.
Prior authorization is almost always required before starting immunotherapy. Your oncologist’s office submits the request, and the insurer typically responds within a few business days. For rare cancers, pediatric cases, or regimens not in the NCCN guidelines, the insurer may still approve coverage if your doctor provides supporting clinical documentation. The key factor is whether the drug has FDA approval for your specific condition. Insurers are far more likely to cover on-label use without pushback.
Off-Label Use and Coverage Gaps
Immunotherapy drugs are sometimes prescribed for cancers or conditions outside their FDA-approved indications. This is called off-label use, and it creates the biggest coverage headaches. Insurers don’t automatically deny off-label claims, but they scrutinize them more heavily. A study tracking off-label immunotherapy prescriptions found that insurers still paid out millions in claims: $7.74 million for commercial insurance patients and $3.85 million for Original Medicare patients in one dataset alone.
Patient costs for off-label therapy varied dramatically by insurance type. Commercially insured patients averaged $657 in out-of-pocket costs, while Original Medicare patients averaged $7,436. Medicaid patients paid nothing. These differences reflect the varying cost-sharing structures across plans and the supplemental coverage some patients carry. If your oncologist recommends an off-label immunotherapy, ask whether they have clinical evidence supporting its use for your cancer type, since that documentation is what the insurer will evaluate.
What to Do if Coverage Is Denied
You have the legal right to appeal any coverage denial. The process has two stages. First, you can file an internal appeal, which requires your insurance company to conduct a full review of its own decision. If your situation is urgent, meaning a delay could seriously harm your health, the insurer must expedite the review. If the internal appeal is denied, you can request an external review, where an independent third party evaluates the case. At that point, the insurance company no longer has the final say.
Your oncologist plays a critical role in appeals. A strong appeal letter includes the clinical rationale for the specific immunotherapy, references to NCCN guidelines or published research supporting its use, and documentation of why alternative treatments are inadequate. Many cancer centers have staff dedicated to navigating insurance appeals, so ask your care team for help rather than trying to manage it alone.
Coverage During Clinical Trials
If you’re considering a clinical trial involving immunotherapy, the costs are split between the trial sponsor and your insurance. The sponsor typically covers research-specific costs: the study drug itself, lab tests done purely for research, extra imaging scans required by the trial protocol, and additional doctor visits beyond what standard care would require.
Your insurance is expected to cover routine patient care costs, meaning everything you’d need even if you weren’t in the trial. That includes doctor visits, hospital stays, standard cancer treatments, side effect management, and standard lab work and imaging. Many states and the Affordable Care Act require insurers to cover these routine costs during qualifying clinical trials, so participation in a trial shouldn’t mean losing coverage for your basic cancer care.
How to Estimate Your Costs
The total price tag for immunotherapy varies enormously depending on the drug, how many cycles you need, and your plan’s cost-sharing structure. Some checkpoint inhibitor treatments run over $150,000 per year at list price. Your actual share depends on your deductible, coinsurance percentage, and whether your plan has an out-of-pocket maximum that caps your annual spending.
Before starting treatment, ask your oncologist’s billing office to run a benefits verification with your insurer. This will tell you exactly what your plan covers, what prior authorization is needed, and what your estimated cost share will be. Most immunotherapy manufacturers also offer patient assistance programs that can reduce copays or provide the drug at no cost for patients who qualify financially. Your oncologist’s office or a hospital financial counselor can connect you with these programs.